Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.34 |
| ▸ | RET | P07949 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660988 | 1.00 | NR1H2 (0.36) | NR1H2NR1H3GPR119UCHL1RET | |
| SCHEMBL13786461 | 0.87 | ADORA1 (0.36) | NR1H2NR1H3GPR119UCHL1MEN1 | |
| SCHEMBL3755529 | 0.81 | NR1H2 (0.37) | NR1H2NR1H3GPR119UCHL1RET | |
| SCHEMBL2910069 | 0.81 | MEN1 (0.36) | NR1H2NR1H3GPR119UCHL1RET | |
| SCHEMBL2910076 | 0.81 | MEN1 (0.36) | NR1H2NR1H3GPR119UCHL1RET | |
| SCHEMBL3661897 | 0.81 | NR1H2 (0.40) | NR1H2NR1H3GPR119UCHL1MEN1 | |
| SCHEMBL3753873 | 0.79 | NOD2 (0.40) | NR1H2NR1H3GPR119UCHL1 | |
| SCHEMBL16203013 | 0.78 | GHSR (0.42) | ALDH1A1 | |
| SCHEMBL24529024 | 0.69 | LMNA (0.45) | UCHL1MEN1KMT2AADORA1ALDH1A1 | |
| SCHEMBL1831292 | 0.68 | MTOR (0.36) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263620-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (SIP) | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20100298373-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2222671-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | Glaxo Group Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009080728-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298373-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | S1PR3, S1PR1, S1PR2 | NR1H2 191/4885NR1H3 159/4885GPR119 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.